Antibodies, binding fragments, and methods of use
NH Lin, CC Huang, CY Chen, CHU Kuo-Ching… - US Patent …, 2020 - Google Patents
2017-09-11 Assigned to OBI PHARMA INC. reassignment OBI PHARMA INC. ASSIGNMENT
OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIN, NAN …
OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LIN, NAN …
Anti-HER2 glycoantibodies and uses thereof
CH Wong, CY Wu - US Patent 10,618,973, 2020 - Google Patents
4,137.230 A 1/1979 Hashimoto et al. the ikMkk antibodies that have not 4,151,042 A 4/1979
Higashide et al. een glycoengıneered. 4.248. 870 A 2/1981 Miyashita et al. 4,256,746 A …
Higashide et al. een glycoengıneered. 4.248. 870 A 2/1981 Miyashita et al. 4,256,746 A …
Methods for modifying human antibodies by glycan engineering
CH Wong, CY Wu - US Patent 11,377,485, 2022 - Google Patents
4,308,269 A 4,309,428 A 4,313,946 A 4,315,929 A 4,317,821 A 4,322,348 A 4,331,598 A
RE30, 985 E 4,361,650 A 4,362,663 A 4,364,866 A 4,371,533 A 4,376,110 A 4,419,446 A …
RE30, 985 E 4,361,650 A 4,362,663 A 4,364,866 A 4,371,533 A 4,376,110 A 4,419,446 A …
Human iNKT cell activation using glycolipids with altered glycosyl groups
CH Wong, LY Alice, KH Lin, WU Tai-Na - US Patent 10,918,714, 2021 - Google Patents
US10918714B2 - Human iNKT cell activation using glycolipids with altered glycosyl groups -
Google Patents US10918714B2 - Human iNKT cell activation using glycolipids with altered …
Google Patents US10918714B2 - Human iNKT cell activation using glycolipids with altered …
Methods of treatment using CCR8 antibodies
S Berndt, C Bertling, P Buchmann, P Ellinger… - US Patent …, 2024 - Google Patents
2024-07-02 Assigned to BAYER HEALTHCARE LLC reassignment BAYER HEALTHCARE
LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS) …
Ccr8 antibodies for therapeutic applications
S Berndt, K Filarsky, H Sabine, H Roider… - US Patent App. 17 …, 2022 - Google Patents
GACDQMDRPRGCTN-KQYNXXCUSA-N 3'-phospho-5'-adenylyl sulfate Chemical
compound C1= NC= 2C (N)= NC= NC= 2N1 [C@@ H] 1O [C@ H](COP (O)(= O) OS (O) …
compound C1= NC= 2C (N)= NC= NC= 2N1 [C@@ H] 1O [C@ H](COP (O)(= O) OS (O) …
Anti-CD20 glycoantibodies and uses thereof
CH Wong, CY Wu, MH Tsai - US Patent 11,884,739, 2024 - Google Patents
GRHWEVYJIHXESA-HBHDJDHDSA-N beta-D-Galp-(1-> 4)-beta-D-GlcpNAc-(1-> 2)-alpha-
D-Manp-(1-> 3)-[beta-D-Galp-(1-> 4)-beta-D-GlcpNAc-(1-> 2)-alpha-D-Manp-(1-> 6)]-beta-D …
D-Manp-(1-> 3)-[beta-D-Galp-(1-> 4)-beta-D-GlcpNAc-(1-> 2)-alpha-D-Manp-(1-> 6)]-beta-D …
Engineered microorganisms for production of 2′ fucosyllactose and l-fucose
US12077792B2 - Engineered microorganisms for production of 2′fucosyllactose and l-fucose
- Google Patents US12077792B2 - Engineered microorganisms for production of 2′fucosyllactose …
- Google Patents US12077792B2 - Engineered microorganisms for production of 2′fucosyllactose …
Combined therapeutic use of antibodies and immunoglobulin g-degrading enzymes
MDM Crispin, CN Scanlan - US Patent App. 16/932,588, 2020 - Google Patents
The invention relates to compositions comprising therapeutic antibodies, and uses and
methods for increasing the potency of therapeutic antibodies. In particular, the invention …
methods for increasing the potency of therapeutic antibodies. In particular, the invention …